Market Research Reports, Business Consulting Services & Analytics
Increasing developments in the gene therapy and enzyme replacement therapies are driving factors for the growth of Pompe disease market.
HYDERABAD, TELANGANA, INDIA, February 13, 2023 /EINPresswire.com/ — Pompe Disease Market size is $1,277Billion in 2019, growing at a CAGR of 3.7% during the forecast period 2020-2025. Pompe disease is also known as GAA deficiency or type II glycogen storage disease (GSD). It is a genetic disorder in which complex sugar called glycogen builds up metabolism in the body’s cells. The disease results from the deficiency of an enzyme called Acid Alfa Glucosidase (GAA), which breaks downs complex sugars in the body. This buildup occurs in organs and tissues, especially in muscles, causing them to break down. The additional glycogen builds up in the patient and is stored in skeletal muscle, heart and other tissues, which causes the progressive indications of pompe disease. It causes muscle weakness and trouble breathing affecting the liver, heart (Cardiomegaly), and muscles that can lead to premature death in the new-born.
Click here to browse the complete report summary:
https://www.industryarc.com/Report/17417/pompe-disease-market.html
Key Takeaways
1. Increased research in the field of Pompe Disease is set to propel the growth of the market.
2. Increasing developments in the gene therapy and enzyme replacement therapies are driving factors for the growth of Pompe disease market.
3. Europe region is estimated to record the fastest growth rate during the forecast period 2020-2025.
Interested in knowing more relevant information? Click here:
https://www.industryarc.com/pdfdownload.php?id=17417
Segment Analysis
1. In 2019, Enzyme Replacement Therapy (ERT) segment dominated the Pompe Disease Market in terms of revenue is estimated to grow at a CAGR of 3.0%. Enzyme Replacement Therapy is used to increase the levels of GAA in the body and reduce the accumulation of glycogen inside cells. It also helps maintain muscle function and improve patients’ quality of life. Lumizyme (alglucosidase alfa) is an FDA approved drug for Enzyme Replacement Therapy abetting towards the market’s growth.
2. In 2019, the North America region dominated Pompe Disease Market in terms of revenue with a market share of 39% owing towards owing to the presence of established payers and an increase in the number of Pompe disease patients in the region.
3. Government has taken initiatives to promote the healthcare expenditure, growing awareness among patients regarding rare disorders in this region are key factors in the growth of the Pompe Disease market.
4. Europe is estimated to record the fastest growth rate during the forecast period 2020-2025.
Competitive Landscape:
The top 5 players in the Pompe Disease Industry are –
1. Amicus Therapeutics
2. Sanofi
3. Audentes Therapeutics
4. Valerion Therapeutics
5. Centogene
Click on the following link to buy the Pompe Disease Market Report:
https://www.industryarc.com/reports/request-quote?id=17417
Why Choose IndustryARC?
IndustryARC is one of the leading market research and consulting firms in the world. It produces over 500 unique market reports annually. If you are looking for a detailed overview of a particular market, you can simply connect with the team at IndustryARC. You can not only buy your preferred market report from the website but also get personalized assistance on specific reports.
Contact Us:
Mr. Venkat Reddy
IndustryARC
Email: [email protected], [email protected]
USA: (+1) 970-236-3677, (+1) 815-656-4596
IND: (+91) 40-485-49062
Venkat Reddy
IndustryARC
+1 614-588-8538
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn
